(secondQuint)Study of Testosterone and rHGH in FSHD.

 This is a single-center, open-label study of daily human growth hormone (Genotropin(R), 5.

0 1/2g/kg via subcutaneous injection) and testosterone (testosterone enanthate, 140mg via intramuscular injection every two weeks) for 24 weeks in men with FSHD with a 12 week washout period.

 A total of 20 subjects will be enrolled at the University of Rochester Medical Center in Rochester, NY.

.

 Study of Testosterone and rHGH in FSHD@highlight

The purpose of this study is to investigate the safety and tolerability of combination therapy with recombinant human growth hormone (rHGH) and testosterone in adult male patients with facioscapulohumeral muscular dystrophy (FSHD) over 24 weeks.

